To the Editor The optimal treatment of intermediate-risk patients with pulmonary embolism (hemodynamically stable patients with right ventricular dysfunction or increased cardiac biomarkers) is an important issue, and the meta-analysis by Dr Chatterjee and colleagues1 showed a reduction in mortality with the use of thrombolysis compared with anticoagulation in this group of patients. However, in my opinion caution is due in interpreting these results.
Bova C. Benefits and Risks Associated With Thrombolysis for Pulmonary Embolism. JAMA. 2014;312(15):1589. doi:10.1001/jama.2014.10786